Is “lean mass loss” the same thing as muscle loss?
Not exactly. Lean mass measured by methods such as DXA includes water, glycogen, and some non-fat tissues in addition to skeletal muscle. Therefore, a reduction in lean mass does not directly mean an equivalent amount of contractile muscle tissue loss. However, preserving muscle tissue during rapid or high-amount weight loss is clinically important; particularly if advanced age, low baseline muscle mass, inadequate protein intake, or physical inactivity are present, the risk of sarcopenia becomes even more significant.
What was seen in the semaglutide studies?
In the DXA sub-analysis of the STEP 1 study, with semaglutide 2.4 mg at 68 weeks, while mean body weight decreased by approximately 15%, total fat mass decreased by 19.3% and total lean body mass decreased by 9.7%. Despite this, the proportion of lean mass within total body weight increased, and the lean/fat ratio improved. This result does not support the claim that “semaglutide selectively wastes muscle”; however, it shows that significant weight loss can also be accompanied by lean mass loss.
What do the tirzepatide data say?
In the SURMOUNT-1 DXA substudy, 160 participants were evaluated. In those receiving tirzepatide, at week 72, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. Approximately 75% of the lost weight was calculated to be fat mass, and 25% lean mass. The researchers reported that this distribution was similar to the proportions seen with other effective weight loss methods. Therefore, the issue is not merely the presence of the drug; it is the rate of total weight loss, baseline body composition, age, nutrition, and exercise regimen.
Why is muscle preservation important?
Muscle tissue is not merely an aesthetic component. It plays an important role in glucose disposal, physical independence, balance and fall risk, resting energy expenditure, and healthy aging. Between two people who achieve the same kilogram loss, the one who preserves muscle better may have a more favorable metabolic and functional profile. For this reason, an approach such as “faster weight loss always means better results” is not accurate.
What does “GLP-1 super responder” mean?
“Super responder” is not an official diagnosis or a standardized clinical category. It is generally a descriptive term used for individuals who experience greater or faster weight loss than expected with semaglutide, tirzepatide, or similar incretin therapies. Studies show that there is significant interindividual variability in treatment response; baseline weight, diabetes status, dose tolerability, appetite response, genetic and behavioral factors may play a role in this.
Why should a very rapid response also be monitored?
A high response is not necessarily bad; visceral fat and metabolic risk can decrease significantly. However, if a rapid energy deficit also reduces protein intake, resistance exercise, and micronutrient intake, the likelihood of problems such as lean mass loss, gallstones, dehydration, hypotension, or hair loss may increase. For this reason, the goal is not only maximum weight loss, but high-quality weight loss.
What did the SEMALEAN study add?
In the prospective SEMALEAN study published in 2026, 115 individuals with obesity were followed under semaglutide 2.4 mg treatment; 106 individuals completed the 12-month evaluation. Body composition with DXA, handgrip strength with a Jamar dynamometer, and resting energy expenditure were measured. Mean weight loss was approximately 10% at month 7 and 13% at month 12. While fat mass decreased by approximately 14% and 18%, respectively, lean mass decreased by approximately 3 kg in the first 7 months and subsequently largely stabilized.
Importantly, handgrip strength increased by approximately 4.1 kg at month 12, and the prevalence of sarcopenic obesity decreased from 49% to 33%. This finding shows that lean mass reduction on DXA does not automatically mean functional muscle loss. Nevertheless, due to the decrease in appendicular skeletal muscle mass, the importance of muscle monitoring continues, particularly in frail and elderly patients.
In whom is muscle monitoring more critical?
- Individuals over 65 years of age
- Those with low baseline muscle mass or low handgrip strength
- Those who lose weight very rapidly or at a very high percentage
- Those with a markedly decreased protein intake
- Those who do not engage in resistance exercise
- Those who remain immobile for long periods or have orthopedic problems
- Those with a history of prior sarcopenia, frailty, or bariatric surgery
New data: Alissou M, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026. Full text.
Protein and resistance exercise
In GLP-1 treatments, decreased appetite sometimes reduces protein intake along with total energy. Especially in older adults and individuals with low baseline muscle mass, the protein content of meals should be consciously planned. Resistance exercise, on the other hand, is one of the primary strategies in preserving muscle function during weight loss by providing mechanical stimulation to muscle tissue. The program should be tailored according to the individual’s age, orthopedic issues, cardiovascular status, and baseline conditioning.
Why is waist circumference as important as the scale?
One of the primary goals of obesity treatment is to reduce metabolically active visceral adipose tissue. Reduction in waist circumference practically helps monitor changes, particularly in abdominal fat. When scale weight, waist circumference, and body composition are evaluated together, a more meaningful picture regarding the quality of treatment is obtained.
Can hair loss really be associated with GLP-1s?
Cohort studies and systematic reviews published in 2026 reported an association signal for non-scarring hair loss and particularly telogen effluvium in individuals using semaglutide and tirzepatide. However, the mechanism is not clear. Rapid weight loss, energy and protein deficit, iron or other micronutrient deficiencies, and physiological stress are potential mediators. Therefore, when hair loss develops, rather than blaming the medication alone, the rate of weight loss, protein intake, ferritin/iron status, and other causes should be evaluated together.
Constipation and dehydration
Nausea, vomiting, diarrhea, and constipation are well-known gastrointestinal side effects of GLP-1 treatments. Slowing of gastric emptying and decreased appetite may also reduce fluid intake. Close monitoring of hydration is especially important in hot weather, in individuals who exercise, in advanced age, or in those using diuretics. Severe or persistent abdominal pain, recurrent vomiting, marked fluid loss, or impaired oral intake require medical evaluation.
Why can weight return when the medication is discontinued?
In the STEP 1 extension study, within one year after semaglutide discontinuation, participants regained approximately two-thirds of their previously lost weight, and a portion of the cardiometabolic gains reverted toward baseline. This finding supports the chronic biology of obesity. If discontinuation of treatment is being considered, nutrition, exercise, a behavioral plan, and, in patients where necessary, a long-term pharmacological strategy should be addressed together.
What can be monitored in the clinic?
Practical follow-up should not consist solely of the question “how much weight did you lose?” In addition to body weight and waist circumference, protein intake, weekly resistance exercise, handgrip strength or similar functional measurements, and, in appropriate cases, body composition methods such as BIA/DXA can be evaluated. This approach is particularly valuable in individuals experiencing rapid weight loss, those over 65 years of age, those at risk of frailty, or those with low baseline muscle mass.
Our approach at our Bodrum clinic
We do not evaluate GLP-1 treatment solely by the scale result. We prefer to monitor weight and waist circumference together with adequate protein, resistance exercise, muscle strength, hydration, and, when needed, body composition. The goal is not merely a lower weight, but to preserve muscle function and metabolic health while increasing fat loss as much as possible.
Limitations of the evidence
The sample sizes of body composition substudies are smaller than those of the main obesity studies. Lean mass measured by DXA is not directly pure muscle tissue. A significant portion of the hair loss data comes from observational studies. Therefore, definitive generalizations should not be made regarding individual risk, dose, and treatment duration.
References
- The Guardian, September 11, 2026: Separating science from marketing claims in GLP-1 drugs
- Look M et al. SURMOUNT-1 body composition substudy. Diabetes Obes Metab. 2025.
- STEP 1: Semaglutide and body composition DXA sub-analysis.
- Wilding JPH et al. Weight regain after semaglutide discontinuation: STEP 1 extension study.
- Herrera HO, Bordeaux JS. Risk of new hair loss with semaglutide and tirzepatide. JAAD. 2026.
Last medical review: September 25, 2026
